How much does generic Gilteritinib cost in Indonesia?
Currently, there is no generic version of Gilteritinib (Gilteritinib) available in the Indonesian market. The demand for giritinib, a targeted treatment for acute myeloid leukemia, is increasing globally, but a generic version of the drug has yet to be introduced into the Indonesian drug market. Since domestic hospital procurement and medical insurance coverage are not yet widespread, it is difficult for patients to obtain the drug directly in Indonesia. Many patients and doctors turn to overseas channels for drug support.
In the international market, giritinib mainly has two types of original drugs and generic drugs to choose from. The original drugs include the European version and the Hong Kong version, especially the Hong Kong version, which is extremely expensive, often as high as 100,000 yuan per box, which is a heavy burden for many patients. In comparison, the prices of foreign generic drugs are relatively affordable, making them the first economic choice for many patients. When patients take medicine, they not only pay attention to the price, but also attach great importance to the quality and efficacy of the medicine.
The price of the Lao version of the generic version of giritinib is very competitive, usually between one thousand and two thousand yuan, which is great news for many patients. Although the price is low, the generic drug is basically consistent with the original drug in terms of drug ingredients and therapeutic effects, and can meet the needs of clinical treatment. Affordable prices not only reduce patients’ financial pressure, but also improve medication accessibility and compliance.
To sum up, although there are no generic drugs of giritinib in Indonesia, patients can purchase the Lao version and other generic drugs through regular overseas channels to obtain cost-effective treatment options. When choosing drugs, patients are advised to confirm the official source of the drugs, ensure the safety of the drugs, and avoid the risks caused by counterfeit and shoddy products, so as to ensure the therapeutic effect.
Reference materials:https://www.xospata.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)